Summit Therapeutics Paid $500 Million for Ivonescimab. The FDA Just Said No.

What does a $500 million bet look like when the regulator refuses to honor it? Ask Summit Therapeutics shareholders, who woke Monday to a stock that had fallen roughly 6% in regular trading after the FDA issued a complete response letter for ivonescimab, the company’s sole commercial priority and one of the most closely watched bispecific antibodies in oncology.

The FDA’s formal refusal covered ivonescimab, a bispecific antibody that blocks two targets at once: the PD-1 immune checkpoint and the VEGF blood-vessel growth signal, developed with China’s Akeso. The phase 3 HARMONi trial underpinning Summit’s application failed to meet its overall survival endpoint, and the FDA stated that a progression-free survival benefit without a statistically significant OS improvement does not support a positive benefit-risk profile in support of approval.

What Summit Actually Bought

The December 2022 licensing agreement granted Summit development and commercialization rights to ivonescimab in the US, Canada, Europe, and Japan for a $500 million upfront payment and up to $4.5 billion in milestones plus low double-digit royalties. That is a price calibrated for a drug that reaches patients. Akeso retained China and rest-of-world rights, capturing both the royalty stream from Summit’s global program and the full commercial upside from a rapidly growing domestic franchise. The asymmetry was always there. The FDA just made it visible.

Ivonescimab clearly slowed disease progression, with a median progression-free survival of 6.8 versus 4.4 months and a hazard ratio of 0.52, but the primary survival analysis missed significance: median OS 16.8 versus 14.0 months, with a hazard ratio of 0.79 and a p-value of 0.057. Later data cuts improved the survival signal, but these were described as nominal and did not persuade the FDA. Summit had argued that Western data was immature at the primary cut; the agency was not moved.

The Broader Problem This Surfaces

The rejection blocks what would have been the first approval in the US of a PD-1xVEGF bispecific, a drug class some analysts think could eventually rival Keytruda. That framing suited the bull case. The bear case, now on the board, is simpler: a drug approved in China on May 24, 2024 and celebrated after a head-to-head China trial against Keytruda could not persuade the FDA that patients in the US live longer on it.

The question for investors is whether this is a data problem or a structural one. Summit cannot rely on Akeso’s China-only trials as a substitute for the evidence package the FDA expects for a US approval, and it must run and fund its own registrational trials. That matters enormously for anyone assessing the pipeline of Western companies that in-licensed Chinese oncology assets on the strength of single-country efficacy data.

Before the FDA issued its rejection, Summit had already parted ways with its chief commercial officer Robert LaCaze and several senior commercial and marketing leaders who were tasked with building ivonescimab’s launch plan. That departure now looks like an early signal the company had lost confidence in a near-term US launch.

What Remains

Jefferies noted the complete response letter was the investor base case and sees limited downside given second-line EGFR was never a key driver of the investment thesis, pointing out that Summit had previously disclosed a lack of alignment with the FDA on this filing. The firm continues to view HARMONi-3 squamous progression-free survival data around year-end 2026 as the defining catalyst for Summit.

In a separate China-only trial, ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment-naïve, PD-L1-positive advanced non-small cell lung cancer. That signal is real. The problem is the FDA does not accept Akeso’s China data as Summit’s evidence. HARMONi-3, the global trial pitting ivonescimab with chemotherapy directly against Keytruda plus chemotherapy in first-line NSCLC, is fully enrolled, with the squamous cohort’s primary progression analysis and an early survival look expected in Q4 2026.

That readout is now the only near-term path to a US approval. If it delivers a clean, statistically significant result, the FDA’s refusal this weekend becomes a detour. If it does not, Summit faces the harder question of what a $500 million upfront payment is worth when Western regulators repeatedly demand evidence the trial design cannot supply.

More From Author

Alibaba Earnings Loom. The Stock Has Been Punished.

Democrats have won but the risks remain

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Categories